[Novel approaches for fundus lesions in high myopia].
Ohno-Matsui
Kyoto
K
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005584:Fovea Centralis; D005654:Fundus Oculi; D006801:Humans; D009216:Myopia / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D041441:Retinoschisis / Q000209:etiology / Q000628:therapy; D012720:Severity of Illness Index; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014821:Vitrectomy
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000068258:Bevacizumab